Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

"Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection" was published as an annex - this guidance made it clear that patient care should not be prejudiced as a result of the procedures to be followed in identifying patients at an increased risk of vCJD.

  • Read more about "Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection" was published as an annex - this guidance made it clear that patient care should not be prejudiced as a result of the procedures to be followed in identifying patients at an increased risk of vCJD.

NHS National Institute for Health and Clinical Excellence published the article "Patient safety and reduction of risk of transmission of Creutzfeldt-Jakob disease (CJD) via interventional procedures".

  • Read more about NHS National Institute for Health and Clinical Excellence published the article "Patient safety and reduction of risk of transmission of Creutzfeldt-Jakob disease (CJD) via interventional procedures".

Morwenna Carrington told the Inquiry about reasons given by the Department of Health as to why a product was not adopted by the NHS in 2007 "as it did not achieve a category 1 rating from the RRP [Rapid Review Panel]. All manufacturers of products are required to have a category 1 rating to be suitable for the NHS. Other manufacturers developing similar pre-soaks also did not achieve a category 1 rating from the RRP and were not recommended for use in the NHS."

  • Read more about Morwenna Carrington told the Inquiry about reasons given by the Department of Health as to why a product was not adopted by the NHS in 2007 "as it did not achieve a category 1 rating from the RRP [Rapid Review Panel]. All manufacturers of products are required to have a category 1 rating to be suitable for the NHS. Other manufacturers developing similar pre-soaks also did not achieve a category 1 rating from the RRP and were not recommended for use in the NHS."

Mr AN told the Inquiry of having to insist upon procedures being carried out in the face of unwillingness from clinicians, and of then being made to wait around until the end of the patient list before being seen, and of having had procedures cancelled on the basis that there was no suitable equipment available.

  • Read more about Mr AN told the Inquiry of having to insist upon procedures being carried out in the face of unwillingness from clinicians, and of then being made to wait around until the end of the patient list before being seen, and of having had procedures cancelled on the basis that there was no suitable equipment available.

A review of three studies conducted between 1995 and 2014 of the prevalence with which abnormal prion proteins seen in samples of appendices removed at operation (hence "appendix studies", as they are known) found that 1 in 2,000 of the population had abnormal prion protein in their appendix.

  • Read more about A review of three studies conducted between 1995 and 2014 of the prevalence with which abnormal prion proteins seen in samples of appendices removed at operation (hence "appendix studies", as they are known) found that 1 in 2,000 of the population had abnormal prion protein in their appendix.

SEAC considered the results of two studies in "Nature" (in advance of their publication at the start of October 1997) and became convinced that the evidence of the link between BSE and vCJD had become "compelling".

  • Read more about SEAC considered the results of two studies in "Nature" (in advance of their publication at the start of October 1997) and became convinced that the evidence of the link between BSE and vCJD had become "compelling".

The "Expert Report to the Infected Blood Inquiry: Statistics" was produced, noting the statistic that no new case of vCJD has been identified since 2016.

  • Read more about The "Expert Report to the Infected Blood Inquiry: Statistics" was produced, noting the statistic that no new case of vCJD has been identified since 2016.

A man was refused a liver biopsy as part of care for Hepatitis B and C.

  • Read more about A man was refused a liver biopsy as part of care for Hepatitis B and C.

A man infected with Hepatitis C told the Inquiry that after being told he was "at-risk" for public health purposes he noticed a significant change in how he was treated by the medical profession, having been made to feel dirty and experiencing frustrating last minute changes of plan.

  • Read more about A man infected with Hepatitis C told the Inquiry that after being told he was "at-risk" for public health purposes he noticed a significant change in how he was treated by the medical profession, having been made to feel dirty and experiencing frustrating last minute changes of plan.

In Dr Hewitt's oral evidence she referred to a case where a recipient developed vCJD, whose family had said that "If they had known that he had been at risk, his last few months would have been dealt with differently...they would have known what they were dealing with, or what they were likely to be dealing with."

  • Read more about In Dr Hewitt's oral evidence she referred to a case where a recipient developed vCJD, whose family had said that "If they had known that he had been at risk, his last few months would have been dealt with differently...they would have known what they were dealing with, or what they were likely to be dealing with."

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 578
  • Page 579
  • Page 580
  • Page 581
  • Current page 582
  • Page 583
  • Page 584
  • Page 585
  • Page 586
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.